Link between Alzheimer’s disease and male hormones

Cognitive dysfunction, including Alzheimer’s disease, has been related to androgen deprivation therapy (ADT). Scientists from Stanford reported that men who were undergoing ADT to treat prostate cancer had significantly increased risk of developing dementia (published in JAMA Oncology). ADT is a common treatment for prostate cancer because the cancer cells usually require androgens, like testosterone, to proliferate. However, the positive impact of ADT on prostate cancer is often temporary, and has important negative side effects. Parsemus Foundation supports ongoing research to better understand the role of testosterone and Alzheimer’s disease.

The situation of altering hormones to treat prostate cancer mimics that of anti-estrogen therapy to treat breast cancer. Our research in a mouse breast cancer model showed that bio identical hormones (rather than anti-hormone therapy) could actually improve outcomes and quality of life.

Linda Brent, PhD

Executive Director, Parsemus Foundation

Tell us what you think

This form does not collect your email address. If you would like us to respond, please send questions to
This field is for validation purposes and should be left unchanged.
We’re sorry, you are not eligible for the nationwide COVID-OUT or ACTIV-6 studies, but you may be eligible for other federal trials:

And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:

Trials Today